



Exploring the Therapeutic Potential of Nootropic Agent Noopept on Depression and Mood Disorders: An Investigative Analysis

Kian Zehtabian ¹ & Dennis Relajo-Howell ²

¹ Islamic Azad University, Tehran Medical Branch (Iran)

² Psychreg (United Kingdom)

ABSTRACT

This article aims to investigate the potential impact of noopept, a synthetic peptide and nootropic agent, on the treatment of depression and mood disorders. Despite a substantial body of research on noopept, the initial investigations focused predominantly on animal models. However, more recent research has investigated its efficacy in humans. Noopept has been shown to enhance acetylcholine signalling, increase the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), protect against glutamate toxicity, and increase inhibitory neurotransmission in the brain. Depression is a common mental disorder characterised by low mood, altered sleep patterns, psychomotor retardation, cognitive sluggishness, and dysregulation of appetite and libido. Despite the fact that noopept is primarily investigated for its neuroprotective and cognitive-enhancing properties, its potential for treating depression and mood disorders remains unexplored. This article examines the potential therapeutic effects of noopept on depression and emphasises the need for additional research in this area.

Keywords: brain; cognitive psychology; depression; mood disorders; noopept

INTRODUCTION

According to Dagda et al. (2023), noopept is a synthetic peptide known to improve human and rodent memory, making it a nootropic agent. Nootropic agents are substances that improve cognitive abilities such as memory, creativity, and focus. The mechanism of action of Noopept is attributed to its antioxidant and anti-inflammatory properties, ability to inhibit the neurotoxicity of excessive calcium and glutamate, and capacity to enhance blood rheology. Ostrovkaya et al. (2007) demonstrated that noopept can aid spatial memory and increase immunoreactivity to A amyloid in a mouse model of Alzheimer's disease following olfactory bulbectomy. In addition, researchers have investigated the therapeutic potential of Noopept for cognitive impairment associated with neurodegenerative diseases such as Parkinson's disease (Anwar & Fathi, 2023; Uddin et al., 2019).

Cognitive enhancers or nootropics have acquired popularity in recent years, particularly in the technology and startup industries, according to Santos and Relajo-Howell (2020). These substances are believed to enhance cognitive abilities such as memory, creativity, and focus, giving consumers a competitive edge in the workplace. However, the use of nootropics is not limited to the workplace. Numerous people use these dietary supplements to enhance their academic performance, enhance their athletic abilities, and promote healthy ageing.

Caffeine, a stimulant found in coffee, tea, and other beverages, is one of the most popular and well-known nootropics. It is favoured for its ability to improve alertness and concentration, and many people rely on

it to increase their productivity. Other commonly used nootropics include omega-3 fatty acids, ginkgo biloba, and creatine, which have demonstrated positive effects on memory, focus, and cognitive flexibility. Although nootropics may appear to be a panacea for enhanced cognitive performance, it is essential to recognise that they are not a replacement for healthy lifestyle choices (Relajo-Howell, 2020). Appropriate rest, regular exercise, and a well-balanced diet are required for optimal cognitive function. Nootropics should be viewed as a supplement to these beneficial habits, not as a replacement.

It is important to note that while nootropics may offer potential benefits for cognitive enhancement, they should not be viewed as a complete solution for optimal brain health. Rather, they should be considered as a complementary tool to support a healthy lifestyle that includes sufficient sleep, regular exercise, and a balanced diet (Pilao et al., 2017). Moreover, the long-term effects of nootropics on brain health and cognitive function have not been fully studied, and therefore, caution should be exercised when using these supplements. While some studies have suggested that nootropics may have positive effects on neuroprotection and healthy ageing, more extensive research is needed to fully understand the potential risks and benefits of these supplements.

Additionally, the long-term implications of nootropics on brain health and cognitive function remain unclear. Although some research has indicated that

Corresponding Author:

Dennis Relajo-Howell

Email: dennis@psychreg.org

Received: May 4, 2023; Accepted: May 19, 2023

nootropics may provide neuroprotective advantages and promote healthy ageing, further investigation is necessary to comprehensively assess the potential risks and benefits of these supplements. Despite the uncertainties surrounding nootropics, they have continued to pique the interest of individuals looking to enhance their cognitive abilities. This burgeoning interest has resulted in the creation of numerous new supplements and drugs, many of which make grandiose assertions about their efficacy. However, just like any other medication or supplement, caution is necessary when dealing with nootropics, and a healthcare professional's advice should be sought before use. Interactions with other drugs or supplements may occur, and certain nootropics may possess unknown risks or side effects (Relajo-Howell, 2021).

While nootropics may provide cognitive benefits, their long-term effects and potential hazards are still not fully understood. To appreciate the possible advantages and drawbacks of these substances, more research is required, and individuals should exercise caution and seek professional advice before using them. In the end, maintaining optimal cognitive function is best achieved through a healthy lifestyle that includes regular exercise, a well-balanced diet, and sufficient sleep. The use of nootropics as cognitive enhancers has grown in recent years, with many people seeking to boost their mental performance. While these supplements may provide some benefits, the potential long-term effects and risks associated with their use are not fully understood. More research is needed to understand how these substances affect the brain and whether they are safe for long-term use.

Experts caution that individuals should not rely solely on nootropics to improve their cognitive function. Instead, they recommend maintaining a healthy lifestyle that includes regular exercise, a balanced diet, and sufficient sleep. These lifestyle factors have been shown to have significant impacts on cognitive function, and they are also associated with other health benefits, such as improved mood and reduced risk of chronic diseases. Furthermore, it is essential to exercise caution when using nootropics, as the quality and safety of these products can vary widely. Consumers should only purchase from reputable sources and should be aware of the potential side effects and interactions with other medications they may be taking. Some of the most popular nootropics include caffeine, creatine, and omega-3 fatty acids. These substances have been shown to improve cognitive function in some studies, but more research is needed to fully understand their effects.

Noopept's prospective cognitive benefits have caught the attention of researchers and healthcare professionals. Extensive research has been conducted on the compound's mechanism of action, which is believed to involve regulating neurotransmitter systems associated with memory formation and controlling glutamate activity (Kondratenko et al., 2010). The substance's neuroprotective attributes, such as its antioxidant and anti-inflammatory properties, and its capacity to impede the neurotoxic effects of excessive calcium and glutamate, suggest its potential usefulness in various neurological disorders

(Dagda et al., 2023).

Various investigations have been conducted to examine the potential of noopept as a viable therapeutic agent for a wide spectrum of neurodegenerative disorders, which encompasses Alzheimer's and Parkinson's disease. Substantive research has demonstrated that noopept has the ability to enhance spatial memory and augment immunoreactivity to A β amyloid in a murine model of Alzheimer's disease. This indicates that noopept has the potential to act as a therapeutic agent for cognitive impairment that is associated with this ailment (Ostrovskaya et al., 2007). Additionally, other investigations have suggested that noopept may also be efficacious in addressing cognitive impairment that is associated with Parkinson's disease (Anwar & Fathi, 2023; Uddin et al., 2019).

In addition to its potential therapeutic utility in treating neurodegenerative disorders, noopept has also been investigated for its ability to enhance cognitive function and improve memory capacity in healthy individuals. Extant research has indicated that noopept can augment learning and memory in both rats and humans and may also have the potential as a remedy for age-related cognitive decline (Ostrovskaya et al., 2014; Malykh & Sadaie, 2010).

Nevertheless, despite the promising results of these studies, it is important to bear in mind that further research is necessary to comprehensively understand the potential benefits and drawbacks of noopept as a therapeutic agent. It is imperative to determine the optimal dosage and duration of treatment, as well as the potential side effects and risks associated with its usage.

Ongoing research

The potential nootropic and neuroprotective effects of noopept have piqued the interest of researchers and medical professionals. The compound's potential to treat neurodegenerative disorders such as Alzheimer's and Parkinson's disease, as well as to improve cognitive function and memory in healthy individuals, has been investigated. While the growing body of evidence supporting the therapeutic potential of noopept is encouraging, additional research is necessary to completely understand the potential benefits and risks of using noopept as a therapeutic agent, including determining the optimal dosage and duration of treatment.

Despite its well-established effects on memory and neuroprotection, noopept's potential applications in the treatment of depression require further study. Depression is a complex mood disorder that affects millions of people worldwide, and it is typically treated with psychotherapy, pharmacotherapy, and other methods. However, traditional therapies for depression are not always effective for all patients, necessitating the development of new treatments. Existing research indicates that noopept may have potential as a complementary or alternative therapy for the treatment of depression. In one study, the effects of noopept and piracetam on depression were investigated using a cell-based model of habituation. Trofimov et al. (2005) found

that the combination of noopept and piracetam had a synergistic effect in diminishing depression in a cellular model. Other studies have also suggested that noopept may have a role in the treatment of depression; however, more research is required to establish its therapeutic utility in this context.

Depression is a significant global mental health concern, characterised by persistent feelings of melancholy, hopelessness, and fatigue, along with disturbed sleep, appetite, and sex drive. Psychotherapy, pharmacotherapy, behavioural rehabilitation, and electroconvulsive therapy are available to alleviate symptoms and enhance functionality (Alexopoulos, 2005; Blackburn et al., 2017; Ogwuche et al., 2020). In order to treat geriatric melancholy, underlying medical conditions must be treated or harmful medications must be discontinued. The potential of noopept as a novel antidepressant represents an intriguing opportunity for mental health professionals to broaden their patients' treatment options.

Although the effects of noopept on memory and neuroprotection are well-established, its potential application in the treatment of depression requires additional study. Since traditional treatments for depression are not effective for all patients, investigating the potential of noopept as a supplementary or alternative treatment may offer a promising new approach to managing depression and related mood disorders. To evaluate the safety and efficacy of noopept in humans and to ascertain the optimal dosage and treatment duration, additional research is required.

To determine the safety and efficacy of noopept in humans, including the appropriate dosage and duration of treatment, additional research is required. Despite promising results from animal studies, it is essential to determine whether these results can be replicated in humans. In addition, noopept's potential as an adjunct therapy for depression requires further investigation to optimise its integration with established therapeutic approaches.

As with any new treatment modality, noopept's safety and efficacy must be thoroughly evaluated prior to its pervasive use in the treatment of depression. The potential of Noopept as a novel antidepressant presents a promising opportunity to expand the range of available treatments. To ensure that the benefits of noopept outweigh any potential risks or side effects, circumspect research is required.

A novel potential strategy

Depression is a pervasive mental health disorder that profoundly affects the lives of millions of people around the globe. Antidepressant drugs, such as selective serotonin reuptake inhibitors (SSRIs), and cognitive-behavioral therapy (CBT) have been the mainstays of traditional approaches to depression treatment to date. The serotonin system of the brain is believed to play a crucial role in the development of depression, with the link between low serotonin levels and depression first proposed in the 1960s and gaining widespread attention

beginning in the 1990s in tandem with the advent of SSRIs (Moncrieff et al., 2022).

Nootropics, also known as "smart drugs", are supplements or drugs that are believed to enhance cognitive function, including memory, creativity, and motivation. While they are not approved by the FDA for medical use, many people use them to boost their productivity or cognitive performance. Noopept is a type of nootropic that has been touted as a potential treatment for depression. It is believed to work by increasing the production of brain-derived neurotrophic factor (BDNF), a protein that is involved in the growth and survival of neurons. Studies have shown that people with depression often have lower levels of BDNF in their brains. While noopept has shown promise in some preliminary studies, more research is needed to determine its safety and effectiveness as a treatment for depression. Mental health professionals caution that nootropics should not be used as a replacement for conventional antidepressants without first consulting with a qualified healthcare professional. It is also worth noting that nootropics are not regulated by the FDA, so the quality and safety of these products can vary widely. People who are considering taking nootropics should do their research and only purchase from reputable sources. Additionally, they should be aware of the potential side effects and interactions with other medications they may be taking.

Several studies have examined the efficacy of noopept in conjunction with other therapeutic agents, such as piracetam. One study, for instance, examined the effects of noopept and piracetam on the suppression of acetylcholine-induced currents in a cellular model of habituation. In a cellular model, the combination of noopept and piracetam was found to have a synergistic effect on depression (Pivoravov et al., 2020). Similar results have been found in other studies, suggesting that noopept may have therapeutic potential for depression.

Studies investigating the potential of noopept as a treatment for depression have yielded encouraging results, highlighting its potential as a novel therapeutic option. However, additional research is necessary to assess its safety and efficacy in humans and to determine the optimal treatment duration and dosage.

The potential of noopept as a novel antidepressant is an encouraging development in the field of mental health. It affords mental health professionals the opportunity to expand the treatment options for depressed patients, whether as a primary or supplementary treatment. In addition, noopept may provide an alternative for patients who do not respond to conventional antidepressants.

Although traditional treatments for depression continue to be effective for many patients, the use of nootropics such as noopept as an alternative or supplementary treatment for depression is a promising area for future investigation. Although additional research is required to ascertain its full potential as a treatment for depression (Gagani et al., 2016), the preliminary findings are encouraging and support the need for additional study in this area.

The potential of noopept as a novel antidepressant is an encouraging development in mental health. It provides a new avenue for mental health professionals to provide care, as it has the potential to expand the variety of available treatment options for patients with depression. In addition, noopept may be a viable alternative for patients who do not respond to conventional antidepressants. While additional research is required to fully comprehend its efficacy, the preliminary findings are encouraging and support the need for further study in this area. As research into noopept and other nootropics continues, innovative and effective treatments for depression may become available in the coming years.

Noopept pathways of function and effects

Previous scientific research has demonstrated that noopept influences multiple brain pathways. This is the first study to demonstrate the antiapoptotic effect of noopept against A β -induced toxicity, demonstrating that noopept increases cell viability in differentiated PC12 cells subjected to A25–35. Pre-treatment with Noopept decreased the proportion of apoptotic cells and inhibited both early and late apoptotic events induced by A. These results are consistent with those obtained with this dipeptide in SH-SY5Y cells exposed to α -synuclein amyloids' toxic effect. The study indicates that noopept has neuroprotective properties as well as the ability to increase mood-regulating neurotransmitters in the brain.

The results of previous scientific studies have suggested that noopept acts on various brain pathways, and the recent study demonstrates its antiapoptotic effect against A β -induced toxicity, indicating its neuroprotective potential and mood-regulating ability. In addition, research by Ostrovskaya et al. (2008) revealed that noopept increases the mRNA expression of neurotrophic factors NGF and BDNF in the rat hippocampus, suggesting a role in neuronal restoration. These findings highlight the potential of noopept as a multifaceted tool in the treatment of various neuropsychiatric disorders, but more research is necessary to determine its full potential.

In their study, Ostrovskaya et al. (2008) examined the effects of noopept on the mRNA expression of the neurotrophic factors NGF and BDNF in the rat hippocampus. Acute administration of noopept increased mRNA expression of both neurotrophins in the hippocampus but not in the cerebral cortex, according to the study. (Ostrovskaya et al., 2008) Chronic administration of noopept caused a modest increase in BDNF expression in the cerebral cortex. Notably, protracted treatment with noopept did not result in the development of tolerance but rather enhanced the neurotrophic effect, which is likely to play a role in neuronal regeneration.

In additional research, the mechanism of action of noopept in the brain has been investigated. Using electrophysiological techniques, Razumovskaya et al. (2019) discovered that noopept increases the activity of NMDA receptors, which are essential for learning and memory processes. This indicates that noopept may enhance cognitive function by enhancing neuronal communication in the brain (Vorobyov et al., 2011). According to a

separate study, noopept modulates the activity of several neurotransmitters, including acetylcholine, dopamine, and serotonin, which are crucial for modulating mood and behaviour (Düzova et al., 2021). These results suggest that noopept may have a wide spectrum of effects on brain function and may be useful in the treatment of a variety of neuropsychiatric disorders.

Despite the fact that noopept has demonstrated promising results in preclinical studies, additional research is required to fully comprehend its therapeutic potential. To evaluate the safety and efficacy of noopept in humans and to determine the optimal dosage and treatment duration, clinical trials are required. Nonetheless, the results of this study provide vital insights into the potential of noopept as a treatment for neurodegenerative diseases and emphasise the need for continued research in this field.

Noopept has shown potential as a treatment for neurodegenerative diseases in preclinical studies. However, it is essential to note that preclinical studies are conducted using animals, and the results do not necessarily translate to humans. To evaluate the safety and efficacy of noopept in humans and to determine the optimal dosage and treatment duration, clinical trials are required.

The results of clinical trials will provide vital insights into the potential of noopept as a treatment for neurodegenerative diseases. Furthermore, these trials will help establish whether noopept is safe and effective for human consumption. The optimal dosage and duration of treatment will also be determined through these clinical trials.

While the results of preclinical studies are promising, it is important to remember that they do not guarantee the safety and efficacy of noopept in humans. Therefore, continued research is necessary to fully comprehend the therapeutic potential of noopept as a treatment for neurodegenerative diseases.

Existing research on the neuropharmacological effects of noopept and the underlying biology of depression suggests that noopept has the potential to serve as a novel antidepressant. However, given that the use of nootropics in this capacity is largely unexplored, the possibility of employing noopept as adjunctive therapy for the treatment of depression warrants further study.

Depression is a complex mood disorder characterised by, among other symptoms, persistent feelings of sorrow, hopelessness, and fatigue. Traditional treatments for depression, such as psychotherapy and pharmacotherapy, have been shown to be effective for many patients. However, not all individuals respond to these interventions, highlighting the need for alternative treatments (Blackburn et al., 2017; Ogwuche et al., 2020). The potential of noopept as a novel antidepressant agent represents an intriguing opportunity to broaden patients' treatment options.

The neuropharmacological effects of noopept are well-documented, and there is evidence that noopept has

a number of neuroprotective and neurotrophic effects. It has been demonstrated that noopept has antioxidant and anti-inflammatory properties, inhibits the neurotoxicity of excessive calcium and glutamate, and improves blood rheology (Dagda et al., 2023). In addition, noopept has been shown to modulate the activity of multiple neurotransmitter systems involved in memory formation and the regulation of glutamate, the brain's most important excitatory neurotransmitter (Kondratenko et al., 2010).

Recent research suggests that noopept may have the potential to be used as a primary or supplementary treatment for depression. Trofimov et al. (2005), for instance, investigated the effects of noopept and piracetam on the inhibition of the acetylcholine-induced current in a cell-based model of habituation. In a cellular model, the combination of noopept and piracetam was found to have a synergistic antidepressant effect. Other studies have also suggested that noopept may have a role in the treatment of depression, but more research is required to completely comprehend its therapeutic utility in this context.

Despite the promising potential of noopept as a novel antidepressant, additional research is required to evaluate the safety and efficacy of noopept in humans and to determine the optimal dosage and duration of treatment. In addition, additional research is required to determine noopept's potential as an adjunctive therapy for the treatment of depression. The use of nootropics in the treatment of depression is largely unexplored, and additional research is required to determine the possibility of employing these agents in this manner.

Existing research on the neuropharmacological effects of noopept and the underlying biology of depression suggests that noopept has the potential to serve as a novel antidepressant. To evaluate the safety and efficacy of noopept in humans and to ascertain the optimal dosage and treatment duration, additional research is required. In addition, more research is required to determine whether noopept could be used as adjunctive therapy for the treatment of depression, as the use of nootropics in this capacity remains largely unexplored. Overall, the potential for noopept to be utilised in the treatment of depression represents an intriguing opportunity to broaden patients' treatment options.

CONCLUSION

The potential of noopept as a therapeutic agent for a variety of neurological and psychiatric disorders is a fascinating and rapidly expanding area of study. As described in this article, previous research has shown that noopept has neuroprotective, antiapoptotic, and antioxidant properties, as well as positive effects on neurotransmitters and brain regions involved in mood regulation and cognitive function.

The potential for noopept to treat depression and other mood disorders is a major focus of noopept research. According to animal studies, noopept may alleviate depressive symptoms by regulating neurotransmitter levels, reducing oxidative stress, and modulating neuroplasticity. In addition, encouraging results from

human clinical trials suggest that noopept may be a safe and effective treatment for depression.

As a potential treatment for depression and other mood disorders, noopept has generated interest in noopept research. Studies on animals indicate that noopept may alleviate depressive symptoms by regulating neurotransmitter levels, decreasing oxidative stress, and modulating neuroplasticity. The results of animal studies have prompted researchers to investigate the therapeutic potential of noopept for other mood disorders. The promising results of animal investigations have also resulted in clinical trials on humans. The encouraging results of these studies suggest that noopept may be a safe and efficacious treatment for depression. To determine the efficacy of noopept as a treatment for other mood disorders, however, more research is required. The potential for noopept to treat depression and other mood disorders is a major focus of noopept research. Animal studies and clinical trials on humans have yielded encouraging results, but additional research is required to fully comprehend the potential of noopept as a treatment for mood disorders.

The potential for noopept to improve cognitive function in healthy individuals and those with cognitive impairments is an additional area of noopept research interest. Studies have shown that noopept can enhance learning and memory by increasing the production of brain-derived neurotrophic factor (BDNF), an essential neuroplasticity-related protein. In addition, noopept has been shown to improve cognitive performance in patients with cognitive impairments such as Alzheimer's disease and traumatic brain injury.

Although the potential benefits of noopept are evident, further research is necessary to ascertain its safety and effectiveness in humans. Future research should focus on determining the optimal dosage and duration of noopept treatment, as well as assessing the possibility of adverse effects. In addition, additional clinical trials are required to confirm the efficacy of noopept as a treatment for neurological and psychiatric disorders.

Growing evidence supporting noopept's potential emphasises the need for additional research in this area. As our understanding of the mechanisms underlying noopept's brain effects advances, we may be able to develop more targeted and effective treatments for a range of neurological and psychiatric disorders. In addition, noopept's potential to enhance cognitive function in healthy individuals may have significant implications for enhancing academic and professional performance.

In conclusion, noopept is a promising new option for treating neurological and mental disorders. Despite the need for additional research, the growing body of evidence supporting its potential emphasises the importance of continuing research in this area. As our understanding of the mechanisms underlying noopept's effects improves, we may be able to devise more targeted and effective treatments for a variety of neurological and psychiatric disorders, thereby improving the lives of those who suffer from these conditions.

REFERENCES

- Acharya, S. & Relajo, D. (2017). Examining the role of cognitive distortion and parental bonding in depressive symptoms among male adolescents: A randomised crossover trial. *Journal of Innovation in Psychology, Education and Didactics*, 21(1), 7–20. <https://doi.org/d9m6>
- Alexopoulos, G. S. (2005). Depression in the elderly. *The Lancet*, 365(9475), 1961–1970. [https://doi.org/10.1016/s0140-6736\(05\)66665-2](https://doi.org/10.1016/s0140-6736(05)66665-2)
- American Psychiatric Association. (2013). *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR)*. American Psychiatric Association.
- Anwar, M. M., & Fathi, M. H. (2023). Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson's disease. *Neurodegenerative Disease Management*. <https://doi.org/10.2217/nmt-2022-0010>
- Blackburn, P., Wilkins-Ho, M., & Wiese, B. S. (2017). Depression in older adults: Diagnosis and management. *British Columbia Medical Journal*, 59(3), 171–177.
- Dagda, R. K., Dagda, R. Y., Vazquez-Mayorga, E., Martinez, B., & Gallahue, A. (2023). Intranasal administration of forskolin and noopept reverses Parkinsonian pathology in PINK1 knockout rats. *International Journal of Molecular Sciences*, 24(1), 690. <https://doi.org/10.3390/ijms24010690>
- Düzova, H., Nazıroğlu, M., Çiğ, B., Gürbüz, P., & Akatlı, A. N. (2021). Noopept attenuates diabetes-mediated neuropathic pain and oxidative hippocampal neurotoxicity via inhibition of TRPV1 channel in rats. *Molecular Neurobiology*, 58(10), 5031–5051. <https://doi.org/10.1007/s12035-021-02478-8>
- Gagani, A., Gemao, J., Relajo, D., Pilao, S.J. (2016). The stages of denial and acceptance among patients with chronic kidney disease. *Journal on Innovation in Psychology, Education and Didactics*, 20(2), 113–114. <https://doi.org/gbzq>
- Gonçalves, J. L., Alves, V. L., Aguiar, J., Teixeira, H. M., & Câmara, J. S. (2019). Synthetic cathinones: an evolving class of new psychoactive substances. *Critical Reviews in Toxicology*, 49(7), 549–566. <https://doi.org/10.1080/10408444.2019.1679087>
- Kondratenko, R. V., Derevyagin, V. I., & Skrebitsky, V. G. (2010). Novel nootropic dipeptide Noopept increases inhibitory synaptic transmission in CA1 pyramidal cells. *Neuroscience letters*, 476(2), 70–73. <https://doi.org/10.1016/j.neulet.2010.04.005>
- Malykh, A. G., & Sadaie, M. R. (2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. *Drugs*, 70, 287–312. <https://doi.org/10.2165/11319230-000000000-00000>
- Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M.A. (2022). The serotonin theory of depression: a systematic umbrella review of the evidence. *Molecular Psychiatry*, 1–14. <https://doi.org/10.1038/s41380-022-01661-0>
- Ogwuche, C.H., Caleb, O., & Relajo-Howell, D. (2020). Perceived stress and social support as predictors of subjective well-being among university students in Nigeria. *Psychology & Society*, 1(79), 120–125. <https://doi.org/10.35774/pis2020.01.120>
- Ostrovskaya, R. U., Gruden, M. A., Bobkova, N. A., Sewell, R. D., Gudasheva, T. A., Samokhin, A. N., Seredinin, S. B., Noppe, W., Sherstnev, V. V., & Morozova-Roche, L. A. (2007). The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model. *Journal of Psychopharmacology*, 21(6), 611–619. <https://doi.org/10.1177/0269881106071335>
- Ostrovskaya, R. U., Gudasheva, T. A., Zaplina, A. P., Vahitova, J. V., Salimgareeva, M. H., Jamidanov, R. S., & Seredenin, S. B. (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. *Bulletin of Experimental Biology and Medicine*, 146, 334–337. <https://doi.org/10.1007/s10517-008-0297-x>
- Patel, S. J., Patel, K. K., Patel, M. S., Md Rupak, A., Patel, Y. B., Sanyal, A. P., Patel, C. P., & Sen, D. J. (2016). Neurostimulants cognitive enhancers as nootropics in multi-task hectic schedule. *World Journal of Pharmaceutical Research*, 3(5), 570–590. <https://doi.org/10.9734/jpri/2021/v33i60b34656>
- Pilao, S.J., Villanueva, A., Gornez, G.R., Villanueva, J.M., & Relajo, D. (2017). Exploring wellness and quality of life among the elderly as a basis for a nursing care plan and psychosocial intervention. *i-manager's Journal on Nursing*, 7(3), 8–15. <https://doi.org/f83x>
- Pinto-Coelho, A. & Relajo, D. (2017). Overview of utilisation of mental health services in Portugal. *Journal of Innovation in Psychology, Education and Didactics*, 21(1), 57–68. <https://doi.org/fkht>
- Pivovarov, A. S., Murzina, G. B., & Vasilyeva, N. V. (2020). Effects of noopept and piracetam on depression of the acetylcholine-induced current in common snail command neurons. *Neuroscience and Behavioral Physiology*, 50, 1012–1017. <https://doi.org/10.1007/s11055-020-01000-2>
- Razumovskaya, M. A., Murzina, G. B., Ostrovskaya, R. U., & Pivovarov, A. S. (2019). Modulation of nicotinic receptors in neurons in the common snail by Noopept and Piracetam. *Neuroscience and Behavioral Physiology*, 49(9), 1127–1134. <https://doi.org/10.1007/s11055-019-00849-2>
- Relajo-Howell, D. (2020, August 28). How to easily improve your mental health. *Psychreg*. Retrieved from: <https://www.psychreg.org/how-to-easily-improve-your->

mental-health

- Relojo-Howell, D. (2021, July 14). How mental health affects your everyday performance. Psychreg. Retrieved from: <https://www.psychreg.org/how-mental-health-affects-your-everyday-performance>
- Santos, A. & Relejo-Howell, D. (2020). Lifestyle and cognitive functioning of Filipino older adults as basis for cognitive enhancement programme. *Psychology & Society*, 4(82), 97–105. <https://doi.org/10.35774/pis2020.04.097>
- Slomp, C., Morris, E., Edwards, L., Hoens, A.M., Landry, G., Riches, L., Ridgway, L., Bryan, S. and Austin, J., 2022. Pharmacogenomic Testing for Major Depression: A Qualitative Study of the Perceptions of People with Lived Experience and Professional Stakeholders. *The Canadian Journal of Psychiatry*, p.07067437221140383. <https://doi.org/10.1177/07067437221140383>
- Trofimov, S. S., Voronina, T. A., & Guzevatykh, L. S. (2005). Early postnatal effects of noopept and piracetam on declarative and procedural memory of adult male and female rats. *Bulletin of Experimental Biology and Medicine*, 139(6), 683–687. <https://doi.org/10.1007/s10517-005-0378-z>
- Uddin, M. S., Al Mamun, A., Kabir, M. T., Jakaria, M., Mathew, B., Barreto, G. E., & Ashraf, G. M. (2019). Nootropic and anti-Alzheimer's actions of medicinal plants: molecular insight into therapeutic potential to alleviate Alzheimer's neuropathology. *Molecular Neurobiology*, 56(7), 4925–4944. <https://doi.org/10.1007/s12035-018-1420-2>
- Vorobyov, V., Kaptsov, V., Kovalev, G., & Sengpiel, F. (2011). Effects of nootropics on the EEG in conscious rats and their modification by glutamatergic inhibitors. *Brain Research Bulletin*, 85(3–4), 123–132. <https://doi.org/10.1016/j.brainresbull.2011.02.011>